

PROVIDER Update



CONTRACTUAL | FEBRUARY 16, 2024 | UPDATE 24-175 | 5 PAGES

New: 1st Quarter 2024 Injectable Medication HCPCS/DOFR Crosswalk

Use the updates for dates of service on and after April 22, 2024

On January 9, 2024, the Pharmacy and Therapeutics (P&T) Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk.

The approved updates, effective April 22, 2024, are listed on pages 2-5 of this update. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net and Community Health Plan of Imperial Valley *Provider Participation Agreement (PPA)*.

The update includes:

- 20 new injectable medications to be added to the DOFR crosswalk.
- 17 updates and changes to injectable medication procedure codes.
- 1 update category
- 12 updates for new generic drugs.

Additional information

Relevant sections of the provider operations manual will be revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library after logging in to the provider portal at provider.healthnetcalifornia.com > *Provider Library* under Quick Links or go directly to providerlibrary.healthnetcalifornia.com.

Providers are encouraged to access the provider portal online at provider.healthnetcalifornia.com for real-time information, including eligibility verification, claims status, prior authorization status, plan summaries, and more.

If you have questions regarding the information contained in this update, contact Community Health Plan of Imperial Valley at 833-236-4141.

THIS UPDATE APPLIES TO MEDI-CAL PROVIDERS:

- Participating Physician Groups

PROVIDER SERVICES

CHPIV Medi-Cal (including ECM and CS providers) – 833-236-4141

PROVIDER PORTAL

provider.healthnetcalifornia.com

Community Health Plan of Imperial Valley ("CHPIV") is the Local Health Authority (LHA) in Imperial County, providing services to Medi-Cal enrollees in Imperial County. CHPIV contracts with Health Net Community Solutions, Inc. to arrange health care services to CHPIV members. *Health Net Community Solutions, Inc. is a subsidiary of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved.

CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by phone or by return fax and destroy this transmission, along with any attachments. If you no longer wish to receive fax notices from Provider Communications, please email us at provider.communications@healthnet.com indicating the fax number(s) covered by your request. We will comply with your request within 30 days or less.

Additions to injectable medication HCPCS/DOFR crosswalk

The following medications have been approved by the Pharmacy and Therapeutics Committee as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table. P&T Committee members include physicians and representatives from participating physician groups (PPGs).

New drugs

HCPCS	Drug name	Generic name	Primary category	Secondary category
Q5132	Abrilada™	Injection, adalimumab-afzb, biosimilar, 10 mg- 0069-0347-02; 40 mg 0069-0319-01.	Therapeutic injection	
Q5132	Abrilada™	Injection, adalimumab-afzb, biosimilar, 20, 40 mg - 00069-0333-02; 00069-0325-01; 00069-0325-02; 00069-0328-02; 00025-0325-02 ; 00025-0328-02; 00025-0333-02; 00025-0325-01	Self-injectable	
J3590	Adzyna	Adamts13 recombinant-krhn	Therapeutic injection	
J3490	Aphexda™	Motixafortide for injection, for subcutaneous use	Therapeutic injection	Chemotherapy adjunctive ¹
C9159	Balfaxar®	Injection, prothrombin complex concentrate (human), per IU of Factor IX activity	Therapeutic injection	Blood/blood products for hemophilia
J3590	Bimzelx®	Bimekizumab-bkzx	Self-injectable	
J3590	Casgevy™	Exagamglogene autotemcel, suspension for intravenous infusion	Therapeutic injection	
J3590	Cosentyx uno	Secukinumab subcutaneous solution auto-injector 300 mg/2 ml	Self-injectable	
J3380	Entyvio® (subcutaneous)	Vedolizumab solution pen-injector 108 mg/0.68 ml 64764-0108-20; 64764-0108-21	Self-injectable	
Q5131	Idacio®	Adalimumab-aacf	Self-injectable	
J3590	Lyfgenia®	Lovotibeglogene autotemcel suspension for intravenous infusion	Therapeutic injection	
J9999	Loqtorzi™	Toripalimab-tpzi IV solution	Therapeutic injection	Chemotherapy ¹
J3590	Omvo™	Mirikizumab-mrkz Intravenous injection 00002-7575-01	Therapeutic injection	

Additions to injectable medication HCPCS/DOFR crosswalk, *continued*

New drugs

HCPCS	Drug name	Generic name	Primary category	Secondary category
J3590	Omvo [™]	Mirikizumab-mrkz subcutaneous injection 00002-8011-01; 00002-8011-27	Self-injectable	
J9324	Pemrydi Rtu [®]	Injection, pemetrexed, 10 mg	Therapeutic injection	Chemotherapy ¹
J3590	Pombiliti [™]	Cipagluco [™] alfa-atga for IV solution	Therapeutic injection	
J1246	Unituxin [®]	Injection, Dinutuximab, 0.1 mg	Therapeutic injection	Chemotherapy ¹
J3490	Wegovy [®]	Semaglutide (weight management) solution	Self-injectable	
J3490	Zepbound [™]	Tirzepatide (weight management) solution	Self-injectable	
J3590	Zymfentra	Infliximab-dyyb injection, for subcutaneous use	Self-injectable	

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

Updates/changes to injectable medication procedure codes or medications

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

HCPCS	Drug name	Generic name	Comment
J0402	Abilify Asimtufii [®]	Aripiprazole IM ER Susp Prefilled Syringe	Replaces C9152
J0391	Artesunate	Injection, artesunate, 1 mg	Replaces J3590
J0184	Barhemsys [®]	Amisulpride (antiemetic) IV solution 10 mg/4 ml	Replaces C9153
J0576	Brixadi [™]	Buprenorphine extended release subcutaneous injection	Replaces G2074
J9286	Columvi [™]	Glofitamab-gxbm injection for intravenous (IV) infusion	Replaces J3590
C9160	Daxxify [®]	Injection, daxibotulinumtoxinA-lanm, 1 unit	Replaces J3590
J1413	Elevidys	Injection, delandistrogene moxeparvovec-rokl, per therapeutic dose	Replaces J3590

Updates/changes to injectable medication procedure codes or medications, *continued*

HCPCS	Drug name	Generic name	Comment
J2508	Elfabrio®	Pegunigalsidase alfa-iwxj injection	Replaces J3590
C9165	Elrexio™	Elranatamab-bcmm Subcutaneous solution 44 mg/1.1 ml	Replaces J3590
C9162	Izervay™	Injection, avacincaptad pegol, 0.1 mg	Replaces J3490
J0217	Lamzede®	Injection, velmanase alfa-tycv, 1 mg	Replaces J3590
J1304	Qalsody™	Tofersen Intrathecal Soln 100 mg/15 ml (6.7 mg/ml)	Replaces C9157
J1412	Rocktavian™	Valoctocogene roxaparvovec-rvox	Replaces J3590
J9333	Rystiggo®	Injection, rozanolixizumab-noli, 1 mg	Replaces J3590
J2781	Syfovre™	Pegcetacoplan injection, for intravitreal use	Replaces J3490
J2679	Uzedly™	Risperidone subcutaneous ER suspension prefilled syringe 200 mg/0.56 ml	Replaces C9158
J9334	Vyvgart® Hytrulo	Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc	Replaces J3590

Category changes

The following medication has been approved by the Pharmacy and Therapeutics Committee to correct the Secondary Category listed below.

HCPCS	Drug name	Generic name	Primary category	Secondary category
J2562	Mozobil® 24 mg/1.2 ml solution	Plerixafor injection	Therapeutic injection	Chemotherapy adjunctive ¹

New generic injectable medications

The following medications have been approved by the Pharmacy and Therapeutics Committee as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table

HCPCS	Drug name	Generic name	Primary category	Secondary category
J1939	Bumetanide	Injection, bumetanide, 0.5 mg	Therapeutic injection	
J9052	Carmustine	Injection, carmustine (accord), not therapeutically equivalent to J9050, 100 mg	Therapeutic injection	Chemotherapy ¹
J0688	Cefazolin	Injection, cefazolin sodium (hikma), not therapeutically equivalent to J0690, 500 mg	Therapeutic injection	Home health/infusion ²
J9072	Cyclophos-phamide	Injection, cyclophosphamide, (Dr. Reddy's), 5 mg	Therapeutic injection	Chemotherapy ¹
J0873	Daptomycin	Injection, daptomycin, not therapeutically equivalent to J0878, 1 mg	Therapeutic injection	Home health/infusion ²
J2679	Fluphenazine	Injection, fluphenazine HCl, 1.25 mg	Therapeutic injection	
J1596	Glycopyrrolate	Injection, glycopyrrolate, 0.1 mg	Therapeutic injection	
J3425	Hydroxo-cobalamin	Injection, hydroxocobalamin, 10 mcg	Therapeutic injection	
J9172	Docetaxel	Injection, docetaxel (ingenus), not therapeutically equivalent to J9171, 1 mg	Therapeutic injection	Chemotherapy ¹
J9255	Methotrexate	Injection, methotrexate (accord), not therapeutically equivalent to J9250 and J9260, 50 mg	Therapeutic injection	Chemotherapy ¹
J2404	Nicardipine	Injection, nicardipine, 0.1 mg	Therapeutic injection	
J9258	Paclitaxel protein-bound particles	Injection, paclitaxel protein-bound particles (teva), not therapeutically equivalent to J9264, 1 mg	Therapeutic injection	Chemotherapy ¹

HCPCS codes were taken from the Centers for Medicare & Medicaid Services HCPCS website at www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html.

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

²When administered by a nurse in a home setting.